Below are the most recent publications written about "Melanoma" by people in Profiles.
-
Milhem MM, Zakharia Y, Davar D, Buchbinder EI, Medina T, Daud A, Ribas A, Chmielowski B, Niu J, Gibney GT, Margolin K, Olszanski AJ, Mehmi I, Sato T, Shaheen M, Zhao L, Kelley H, Liu H, Kumar S, Bobilev D, Krieg AM, Wooldridge JE, Kirkwood JM. Intratumoral vidutolimod as monotherapy or in combination with pembrolizumab in patients with programmed cell death 1 blockade-resistant melanoma: Final analysis from a phase 1b study. Cancer. 2025 Aug 01; 131(15):e70022.
-
Manne SL, Kashy DA, Pagoto S, Peterson SK, Heckman CJ, Gallo J, Berger A, Buller DB, Kulik A, Frederick S, Pesanelli M. Engagement in and correlates of total cutaneous exams and skin self-exams among young melanoma survivors and their family. J Behav Med. 2025 Oct; 48(5):834-847.
-
Murata K, Minowa T, Tsukahara T, Yoshida T, Minami A, Nakatsugawa M, Mizue Y, Murai A, Tokita S, Sasaki K, Uhara H, Kubo T, Kanaseki T, Torigoe T, Hirohashi Y. An SNP-dependent cancer-testis antigenic epitope serves as a promising immunotherapeutic target for cancer. Oncoimmunology. 2025 Dec; 14(1):2528110.
-
Moncayo AK, Ferguson JM, Dizon MP, Huhmann L, Kim DY, Do N, Brophy MT, Osborne TF, Spence AC, Fillmore NR, Swetter SM, Hartman RI. Area Deprivation Index and Melanoma Thickness in Veterans. JAMA Dermatol. 2025 Jun 01; 161(6):582-588.
-
Sorroche BP, de Jesus Teixeira R, de Souza VG, Tosi IC, Tostes K, Laus AC, Santana IVV, de Lima Vazquez V, Arantes LMRB. CD24, NFIL3, FN1, and KLRK1 signature predicts melanoma immunotherapy response and survival. J Mol Med (Berl). 2025 Jun; 103(6):725-737.
-
Ricardo JW, Bellet JS, Jellinek N, Lee D, Miller CJ, Piraccini BM, Richert B, Rubin AI, Lipner SR. Evaluation and diagnosis of longitudinal melanonychia: A clinical review by a nail expert group. J Am Acad Dermatol. 2025 Jul; 93(1):176-187.
-
Davar D, Morrison RM, Dzutsev AK, Karunamurthy A, Chauvin JM, Amatore F, Deutsch JS, Das Neves RX, Rodrigues RR, McCulloch JA, Wang H, Hartman DJ, Badger JH, Fernandes MR, Bai Y, Sun J, Cole AM, Aggarwal P, Fang JR, Deitrick C, Bao R, Duvvuri U, Sridharan SS, Kim SW, A Choudry H, Holtzman MP, Pingpank JF, O'Toole JP, DeBlasio R, Jin Y, Ding Q, Gao W, Groetsch C, Pagliano O, Rose A, Urban C, Singh J, Divarkar P, Mauro D, Bobilev D, Wooldridge J, Krieg AM, Fury MG, Whiteaker JR, Zhao L, Paulovich AG, Najjar YG, Luke JJ, Kirkwood JM, Taube JM, Park HJ, Trinchieri G, Zarour HM. Neoadjuvant vidutolimod and nivolumab in high-risk resectable melanoma: A prospective phase II trial. Cancer Cell. 2024 Nov 11; 42(11):1898-1918.e12.
-
Sari G, Dhatchinamoorthy K, Orellano-Ariza L, Ferreira LM, Brehm MA, Rock K. IRF2 loss is associated with reduced MHC I pathway transcripts in subsets of most human cancers and causes resistance to checkpoint immunotherapy in human and mouse melanomas. J Exp Clin Cancer Res. 2024 Oct 02; 43(1):276.
-
Celhar T, Li X, Zhao Y, Tay HC, Lee A, Liew HH, Shepherdson EK, Rajarethinam R, Fan Y, Mak A, Chan JKY, Singhal A, Takahashi T. Fetal liver CD34+ contain human immune and endothelial progenitors and mediate solid tumor rejection in NOG mice. Stem Cell Res Ther. 2024 06 09; 15(1):164.
-
Kim DY, Behbahani S, Moncayo A, Trepanowski N, Hartman RI. Disparities in melanoma presentation and overall survival among disaggregated Hispanic nationalities: A retrospective analysis of 2,517 patients in the National Cancer Database. Arch Dermatol Res. 2024 Jun 08; 316(7):377.